Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Relating to restricting the collection and use of DNA samples from children in the managing conservatorship of the Department of Family and Protective Services.
Relating to prohibited retaliation against a physician or health care provider for reporting certain violations or taking certain actions with respect to the provision of health care services; providing a civil remedy.
Relating to the instructional materials for certain curriculum in public schools, including certain instructional prohibitions and requirements regarding those materials.